悦康药业：子公司乙肝新药获中美临床试验批准

Core Viewpoint - YKYY013 injection, a product of YKYY013, has received NMPA approval to conduct Phase I clinical trials for chronic hepatitis B virus infection, indicating a significant advancement in the company's drug development pipeline [1] Company Summary - YKYY013 injection is a GalNAc-conjugated double-stranded siRNA, which has shown inhibitory activity against all ten genotypes of HBV in preclinical studies [1] - Animal trials demonstrated a significant reduction in HBV DNA and HBsAg levels, as well as the induction of HBsAb production [1] Industry Summary - The approval for clinical trials reflects ongoing innovation and research in the field of hepatitis B treatments, highlighting the potential for new therapeutic options in the market [1]